inflammatory bowel disease tagged posts

High magnification micrograph of Crohn’s disease. Biopsy of esophagus. H&E stain. Credit: Nephron/Wikipedia

A single protein from a worm parasite may one day offer new therapeutic options for treating inflammatory bowel diseases like Crohn’s or Ulcerative Colitis, that avoid the potentially serious side effects of current immunosuppressant medications. The study, published today in Nature Communications, demonstrates the discovery of a distinct new worm protein which mimics a cytokine found in humans, known as transforming growth factor-beta (TGF-β). The newly-discovered protein switches off inflammation by inducing “regulatory T cells”, the body’s own means of dampening excessive reactivity.

The “Hygiene Hypothesis” suggests that some bugs and parasites may protect you from an overly-rea...

Administration of titanium dioxide (TiO2) nanoparticles aggravates colitis in the dextran sodium sulfate (DSS) mouse model of acute colitis through activation of the nucleotide-binding oligomerisation domain receptor, pyrin domain containing (NLRP)3 inflammasome.

Titanium dioxide, one of the most-produced nanoparticles worldwide, is being used increasingly in foodstuffs. When intestinal cells absorb titanium dioxide particles, this leads to increased inflammation and damage to the intestinal mucosa in mice with colitis. Researchers at the University of Zurich recommend that patients with colitis should avoid food containing titanium dioxide particles.

The frequency of inflammatory bowel disease like Crohn’s disease and ulcerative colitis has been on the rise in many Western countries for d...

Inflamed mouse colon mucosa, with an expanded population of intestinal stromal cells identified by expression of podoplanin (green). Epithelium is identified by expression of EpCAM (magenta); cyan, nuclei. Credit: Dr. Samuel Bullers

Kennedy Institute of Rheumatology and Translational Gastroenterology Unit, University of Oxford have identified a potential therapeutic target for IBD. The findings are of particular importance to the 40% of patients who don’t respond to anti-TNF therapy, the current treatment option available. The new study published in Nature Medicine shows that IBD patients have higher concentrations of Oncostatin M (OSM), a protein linked to inflammation, in their intestine and suggest that blocking OSM could prove to be a successful treatment for IBD.

The research also sho...